Aim: To assess the efficacy and safety of pasireotide long-acting release (PAS-LAR) alone or in combination with pegvisomant by switching patients with acromegaly who were well controlled with long-acting somatostatin analogues (LA-SSAs) and pegvisomant to PAS-LAR with or without pegvisomant.
A cromegaly is an endocrine disorder predominantly caused by a pituitary adenoma characterized by excess growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion. Persistently elevated GH and IGF-I levels result in reduced life expectancy, reduced quality of life, and multisystem comorbidities (1) . Normalization of GH and IGF-I normalizes life expectancy and improves quality of life and comorbidities (2) . Current medical treatment regimens focus on inhibiting pituitary GH hypersecretion and blocking peripheral GH actions.
First-generation long-acting somatostatin analogues (LA-SSAs) such as octreotide long-acting release (LAR) and lanreotide autogel (ATG) are the cornerstones of the pharmacological treatment of acromegaly. They inhibit pituitary GH secretion by preferential binding to somatostatin receptor subtype 2 (SSTR2). In clinical practice only, ;40% of patients treated with monotherapy LA-SSAs achieve biochemical normalization of GH and IGF-I. Therefore, most patients treated with LASSAs need additional therapies (3) (4) (5) .
The GH receptor antagonist pegvisomant (PEGV) is a competitive GH receptor blocker and the most effective drug to normalize IGF-I levels in acromegaly. IGF-I normalization can be achieved in 60% to .90% of patients, provided that the dose is sufficiently increased (6) (7) (8) (9) (10) (11) . Importantly, PEGV improves glucose homeostasis by increasing hepatic and peripheral insulin sensitivity, even after normalization of GH and IGF-I levels (12) (13) (14) (15) . Combination treatment of LA-SSA and PEGV shows similar high efficacy of .90%, with the added benefit of lowering the required PEGV dose (16, 17) .
Pasireotide LAR (PAS-LAR) is a second-generation LA-SSA that targets multiple somatostatin receptors, with the highest affinity for SSTR5, followed by SSTR2, SSTR3, and SSTR1. Compared with octreotide and lanreotide, pasireotide has a higher affinity for SSTR5 and a lower affinity for SSTR2 (18) . PAS-LAR has been shown to provide superior clinical efficacy over octreotide LAR. This has been shown in two clinical trials: in treatment-naïve patients with acromegaly and in patients inadequately controlled with LA-SSAs (19, 20) . Although the effect of PAS-LAR and octreotide LAR on the reduction of GH levels is superimposable, PAS-LAR appears to be more effective in lowering IGF-I levels (19) .
PAS-LAR has a similar safety profile to LA-SSAs, with the exception of a higher frequency and degree of hyperglycemia-related adverse events (AEs), which have been reported in ;60% of patients (19) . These are presumably caused by a suppression of insulin secretion and a reduced incretin response (21) (22) (23) .
The combination treatment of PEGV with PAS-LAR has not been extensively studied. A potential advantage of this combination may be a reduction in the PEGV dose to control acromegaly activity. This PEGV-sparing effect of PAS-LAR could lead to a reduction in the number of patients who need PEGV cotreatment or a reduction in the number of injections of PEGV and, thereby, a reduction of costs of this treatment.
The effects of combination treatment of PEGV and PAS-LAR on glucose homeostasis are unknown. We hypothesized that the improvement of glucose homeostasis with PEGV may offset PAS-LAR-induced hyperglycemia.
The aim of the current study was to assess the efficacy and safety of PAS-LAR alone or in combination with PEGV by switching patients with acromegaly who were well controlled with LA-SSAs and PEGV to PAS-LAR with or without PEGV in a prospective open-label trial.
Methods

Study design
The pasireotide LAR and pegvisomant (PAPE) study is a 24-week, prospective, single-center, open-label, investigatorinitiated conversion study. We recruited patients from the Erasmus University Medical Center outpatient clinic. After enrollment, LA-SSA treatment was continued, and the PEGV dose was reduced by 50% in the first 12 weeks (run-in phase, Fig. 1 ). When IGF-I levels remained within the reference range [IGF-I #1.2 3 upper limit of normal (ULN)] after 12 weeks, patients were switched to PAS-LAR 60 mg monotherapy every 4 weeks. When IGF-I levels exceeded 1.2 3 ULN after 12 weeks, patients were switched to PAS-LAR 60 mg while the 50% reduced PEGV dose was continued. Between 12 and 24 weeks, dose adaptations of PEGV were not permitted unless IGF-I decreased below the age-adjusted normal limits. In that case, the dose of PEGV was decreased by 20 mg weekly, until IGF-I increased to age-specific reference ranges. PAS-LAR injections were administered at home by endocrine nurses, and PEGV injections were administered by patients themselves.
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and reported in accordance with the International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical Practice. The study protocol was approved by the medical ethics committee of the Erasmus University Medical Centre. An independent Data Safety Monitoring Board was established for the purpose of safety surveillance to perform interim analyses on the safety and efficacy data and to evaluate patient safety and scientific integrity. The Data Safety Monitoring Board consisted of a clinical expert in endocrinology and a clinical epidemiologist. All patients provided written informed consent to participate in the PAPE study. This study was registered with ClinicalTrials.gov as NCT02668172, the Dutch Trial Register, and the World Health Organization International Clinical Trials Registry Platform as NTR5282.
Patients
We enrolled 61 (32 male) patients, aged 18 years or older, with well-controlled acromegaly (defined as IGF-I concentration #1.2 times the age-and sex-adjusted ULN). At study entry eligible patients had received combination treatment with weekly PEGV and monthly injections of either 30 mg octreotide LAR or 120 mg lanreotide ATG for at least 6 months prior to study. Eight patients received LA-SSAs every 3 weeks. Two patients who also used the dopamine receptor agonist cabergoline were also included, but their dose of cabergoline was not changed during the study period. Key exclusion criteria included diabetic patients with poor glycemic control, defined as hemoglobin A1c (HbA1c) levels $9.0%; pituitary surgery or radiotherapy within the previous 6 months; patients with compression of the optic chiasm causing any visual field defect that required acute surgical intervention; patients with risk factors for torsades de pointes (i.e., patients with a baseline QTcF .450 ms in males and .460 ms in females); patients who had congestive heart failure (New York Heart Association class III or IV), unstable angina, sustained ventricular tachycardia, clinically relevant bradycardia, advanced heart block, history of acute myocardial infarction ,1 year prior to study entry or clinically relevant impairment in cardiovascular function; patients diagnosed with liver disease such as cirrhosis or chronic active hepatitis; patients with an abnormal hepatic function, defined as alanine aminotransferase (ALT), aspartate aminotransferase (AST), g-glutamyltransferase, alkaline phosphatase, or total bilirubin more than three times the ULN; patients with symptomatic cholelithiasis and/or chronic pancreatitis; patients with renal insufficiency, defined as clearance ,50 mL/min; and patients with hypothyroidism or adrenal insufficiency who are not on adequate replacement therapy.
Procedures
Blood measurements
Total IGF-I, and GH concentrations were measured with the commercially available immunometric assay (IDS-iSYS; Immunodiagnostic Systems Limited, Boldon, UK). IGF-I intra-assay and interassay coefficients of variation were respectively 5.7% to 8.1% and 1.5% to 2.1%, and IGF-I was interpreted according to the sex-and age-dependent ranges by Bidlingmaier et al. (24) . PEGV did not interfere with the GH immunoassay that was used (25) . Fasting plasma glucose; insulin; HbA1c levels; serum concentrations of ALT, AST, alkaline phosphatase, glutamyl transpeptidase, and total bilirubin; coagulation; and kidney function were determined with standard laboratory methods.
Study assessments
Safety assessments included electrocardiogram at baseline and 24 weeks. The severity of AEs was evaluated at every study visit as mild (grade 1), moderate (grade 2), severe (grade 3), or life-threatening (grade 4) according to the Common Terminology Criteria for Adverse Events (26) . With respect to hyperglycemia-related AEs, grade 1 was defined as a fasting glucose value of .6.1 to 8.9 mmol/L; grade 2, .8.9 to 13.9 mmol/L; grade 3, .13.9 to 27.8 mmol/L or requiring hospitalization; and grade 4, .7.8 mmol/L.
Outcomes
The primary efficacy end point was descriptive in nature and was defined as the percentage of responders at 24 weeks in the intention-to-treat population in each treatment arm (PAS-LAR monotherapy, PAS-LAR/PEGV combination treatment), with an exact 95% confidence interval (CI). Response was defined, similar to the inclusion criteria, as IGF-I #1.2 3 ULN. For missing data, imputation based on last observation carried forward was used. Secondary descriptive endpoints for efficacy included the cumulative PEGV dose reduction at 24 weeks compared with baseline. Secondary endpoints for safety included the incidence of AEs, incidence of hyperglycemia and diabetes, vital signs, clinical examination, electrocardiogram, standard hematology, kidney function, endocrine function tests, and serum concentrations of ALT, AST, alkaline phosphatase, glutamyl transpeptidase, and total bilirubin.
Changes in diabetic category during the study were determined using the following American Diabetes Association criteria (27):
• Normal glucose tolerance: fasting plasma glucose ,5.7 mmol/L and/or HbA1c ,5.7%
• Prediabetes: fasting plasma glucose $5.7 to ,7 mmol/L and/or HbA1c $5.7% to ,6.5% Figure 1 . PAPE study design.
• Diabetes: patients taking antidiabetic medication or having fasting plasma glucose $7.0 mmol/L or HbA1c $6.5%
The power calculation for the primary endpoint was based on a prospective randomized double-blind phase III study of Colao et al. (19) . In this study, medically naïve or postsurgery patients with acromegaly were randomized to PAS-LAR 40 mg or octreotide LAR 20 mg every 28 days. The results revealed that after 1 year, 38.8% of patients on PAS-LAR achieved normal IGF-I levels compared with 23.6% on octreotide LAR. In this head-to-head superiority study, PAS-LAR showed an overall response rate of ;60% more in the pasireotide group (19) . Therefore, we estimated that PAS-LAR had 40% higher efficacy than first-generation LA-SSAs. The 95% CI was calculated using a percentage ranging from 25% to 40%. Statistical analyses were performed using SPSS software (version 24 for Windows; SPSS, Inc., Chicago, IL) and GraphPad Prism version 6.04 (GraphPad Software, San Diego, CA). Categorical data were represented as observed frequencies and percentages. Continuous data were represented as mean and 95% CI or median and range. The Kolmogorov-Smirnov and the Shapiro-Wilk test were used to test normality of variables. If assumption of normality was met, the paired t test was used. For nonnormally distributed variables, the Wilcoxon signed-rank test was used. We considered P values of ,0.05 to be statistically significant.
Results
Between 24 August 2015 and 26 July 2016, 100 patients with acromegaly were screened and 61 patients were enrolled in the PAPE study (Supplemental Fig. 1 ). These patients comprised the intention-to-treat set. Table 1 shows the patients' baseline clinical and biochemical characteristics. The mean age was 53 years, the median time since diagnosis was 8.9 years, and the median time since start of combination treatment was 6.1 years. Of the patients, 44.2% had previously received surgery and seven patients (11.5%) had previously received radiotherapy after surgery. The prevalence of diabetes was 32.8% at baseline, and 20% of these patients were managed with oral antidiabetic therapy, whereas three patients were on insulin therapy.
Efficacy
In Fig. 2A , IGF-I levels and the PEGV doses are shown. At baseline, the mean IGF-I was 0.97 3 ULN (95% CI, 0.91 to 1.02) with a mean PEGV dose of 134 mg/wk (95% CI, 103 to 166). At 12 weeks, as by protocol, the mean PEGV dose was decreased to 61 mg/wk (95% CI, 44 to 78), and IGF-I levels increased to 1.59 3 ULN (95% CI, 1.45 to 1.73). In 15 (24.6%) patients, IGF-I levels remained within the reference range, so they were switched to PAS-LAR 60 mg monthly as monotherapy, whereas the remaining 46 (75.4%) of patients with elevated IGF-I levels continued with their reduced dose of PEGV treatment but now in combination with PAS-LAR 60 mg monthly. After 24 weeks from baseline, IGF-I levels dropped back to within the normal range in 45 (73.8%) patients (mean IGF-I of 1.04 3 ULN; 95% CI, 0.91 to 1.17). Stratified by treatment, IGF-I levels within the reference range could be induced in 14 of 15 (93.3%) patients in the PAS-LAR monotherapy group and in 31 of 46 (67.4%) patients in the PAS-LAR/PEGV combination group. After 24 weeks from baseline, the mean PEGV dose could be further decreased to 48 mg/wk (95% CI, 21 to 74), whereas PEGV could be discontinued in 67.8% of patients. The cumulative reduction in PEGV dose was 66.1% in all patients at 24 weeks compared with baseline.
GH levels decreased significantly during the study (Fig. 2B) . At baseline, the mean GH level was 9.3 mg/L (95% CI, 4.3 to 13.9) and significantly decreased to 7.4 mg/L (95% CI, 3.1 to 11.7; P , 0.0001) after 12 weeks, whereas IGF-I levels increased significantly in the same time period. After 24 weeks, after subsequent treatment with PAS-LAR, mean GH levels further decreased significantly to 5.5 mg/L (95% CI, 1.3 to 9.6; P , 0.0001). Stratified to treatment group, in the PAS-LAR monotherapy group, mean GH levels decreased from 2.5 mg/L (baseline) (95% CI, 0.9 to 4.2) to 0.6 mg/L (24 weeks) (95% CI, 0.3 to 0.8). In the PAS-LAR/PEGV combination group, mean GH levels decreased from 11.5 mg/L (baseline) (95% CI, 5.6 to 17.5) to 7.3 mg/L (24 weeks) (95% CI, 1.7 to 3.0).
In Supplemental Table 1 , the differences are shown between patients who did achieve and who did not achieve IGF-I normalization at 24 weeks. Patients who were biochemically controlled at 24 weeks were using a significantly lower baseline PEGV dose and had a lower baseline bodyweight. Between biochemically controlled and noncontrolled patients, we found no difference in age, sex, body mass index (BMI), HbA1c, and presence of diabetes. After correction for age and baseline bodyweight, the baseline PEGV dose was the most important predictor for IGF-I levels at 24 weeks with an odds ratio of 0.986 (95% CI, 0.976 to 0.996) (Supplemental Table 2 ). In clinical terms, a lower weekly PEGV dose at baseline increased the chance of reaching normal IGF-I levels within the reference range after 24 weeks (for each 10-mg PEGV reduction, the increase of IGF-I levels within the reference range was 14.0%).
Hyperglycemia and diabetes
The most common recorded AE during the study was hyperglycemia (Table 2) . We noted a total of 54 (88.5%) AEs were hyperglycemia related, of which 40 (65.6%) were grades 1 and 2. Grade 3 and 4 hyperglycemias were reported in 14 (23.0%) patients and were all related to PAS-LAR treatment.
Mean fasting plasma glucose and HbA1c concentrations rose slightly between baseline and 12 weeks but increased significantly after the start of PAS-LAR treatment (Fig. 3) . Between 12 and 24 weeks, mean fasting plasma glucose rose from 6.1 mmol/L (95% CI, 5.9 to 6.3) to 9.1 mmol/L (95% CI, 8.1 to 10.1) (P , 0.0001) and HbA1c from 6.1% (95% CI, 5.9 to 6.3) to 7.3% (95% CI, 6.9 to 7.7) (P , 0.0001). Although 20 (32.8%) patients had diabetes at baseline, this number doubled to 42 (68.9%) patients at 24 weeks. At 24 weeks, diabetic patients had a significantly higher baseline HbA1c compared with nondiabetic patients (Supplemental Table 3 ). Diabetic patients were insignificantly slightly older. Between diabetic and nondiabetic patients, we found no differences in sex, PEGV dose at baseline, IGF-I at 12 weeks, weight, or BMI. After correction for fasting plasma glucose levels and age, baseline HbA1c was the most important predictor for development of diabetes at 24 weeks. Logistic regression analysis of HbA1c tertiles revealed that patients in the second and third tertiles had increased odds (odds ratio, 5.5 and 55.0, respectively) of developing diabetes at 24 weeks compared with patients in the lowest HbA1c tertile (Supplemental Tables 4  and 5) .
After 24 weeks, nearly a third (31.1%) of patients required no change or initiation of antidiabetic medication, whereas most patients required a combination of metformin and a dipeptidyl peptidase 4 (DPP-4) inhibitor (Table 3) . Seven patients required at least one antidiabetic drug. Three patients had to start insulin treatment, of whom two patients developed serious AEs involving severe hyperglycemia after the first PAS-LAR injection. These patients had preexisting diabetes that was managed with either maximum oral antidiabetic drugs, a glucagon-like peptide 1 analogue, or insulin treatment. After initiation of insulin treatment, PAS-LAR treatment was discontinued, and they were all switched back to their previous LA-SSA and PEGV treatment, after which their diabetes recovered completely (supplemental data).
Nondiabetes-related AEs
In the run-in phase during reduction of the PEGV dose, 28 of 61 (46%) patients developed symptoms of active acromegaly such as fatigue, increased sweating, arthralgia, and headache. We observed no transient elevated transaminases during the study. Two-thirds (12 of 18) of patients with diarrhea experienced symptoms of steatorrhea. These symptoms were generally mild and transient. Although no diagnostic evaluation was performed to confirm exocrine pancreatic insufficiency, patients generally experienced symptomatic improvement with temporary pancreatic enzyme supplementation.
Discussion
To our knowledge, the PAPE study is the first study to assess the efficacy and safety of PAS-LAR in patients with acromegaly previously using combination treatment of first-generation LA-SSAs and PEGV. Our results show that 12 weeks of PAS-LAR treatment results in a 66.1% reduction in PEGV dose, whereas 73.8% of the patients attain IGF-I within the reference range (#1.2 ULN) . Moreover, 67.8% of patients could discontinue PEGV at 24 weeks. These findings indicate that PAS-LAR has an important PEGV-sparing effect. However, this came at the expense of a higher frequency of diabetes, which doubled from 32.8% at baseline to 68.9% after 24 weeks of treatment.
The patients who had normal IGF-I levels at 12 weeks (PAS-LAR monotherapy group) had a significantly lower baseline PEGV dose than those with elevated IGF-I levels at 12 weeks (combination treatment group): 64 mg/wk (95% CI, 50 to 78) vs 157 mg/wk (95% CI, 118 to 197) (P = 0.008). Furthermore, patients in the PAS-LAR group also had significantly lower baseline IGF-I levels than those in the combination treatment group: 0.83 3 ULN (95% CI, 0.71 to 0.95) vs 1.01 3 ULN (95% CI, 0.96 to 1.07) (P = 0.002). The observed trend of a higher frequency of patients after radiotherapy in the PAS-LAR monotherapy group (20.0%) compared with the combination treatment group (6.5%) was not statistically significant (P = 0.15). We found no differences in the frequency of previous surgery between both groups. Apparently, patients in the PAS-LAR group have a lower disease activity at baseline, which is reflected by their lower baseline PEGV dose, IGF-I level, and GH level, or they are more sensitive to LA-SSA, possibly due to a higher SSTR2 expression.
An additional interesting observation is the rapid decrease in IGF-I levels after the first injection of PAS-LAR. This observation could be related to a decrease in insulin secretion, which reduces IGF-I production (28) . After two PAS-LAR 60-mg injections, mean IGF-I levels decreased from 1.59 3 ULN (95% CI, 1.45 to 1.73) to 1.08 3 ULN (95% CI, 0.95 to 1.22). We cannot rule out a carryover effect of LA-SSAs, but these rapid reductions are usually not observed during treatment with firstgeneration LA-SSA.
After the reduction in the PEGV dose during the first 12 weeks, mean GH levels decreased, whereas IGF-I levels increased. This finding is compatible with reports of increased GH levels during PEGV treatment (6) . At 24 weeks, GH levels were further significantly decreased in all subjects, both in the PAS-LAR monotherapy as in the PAS-LAR and PEGV group. Probably, the lower GH levels can be explained by the discontinuation of or Patients may have taken more than one antidiabetic medication.
Abbreviation: GLP1, glucagon-like peptide 1. further dose reduction in PEGV, plus the additional suppressive effect of PAS-LAR on GH secretion. In our study, the frequency of hyperglycemia-related AEs was higher (88.5%) than in previous studies (19, 20, (29) (30) (31) , but the increase in frequency of diabetes (32.9% at baseline to 68.9% at 24 weeks) is in line with the pasireotide vs octreotide or lanreotide (PAOLA) study (22% to 70%) (20) . The higher frequency of hyperglycemia-related AEs could be explained by the inclusion of older subjects, because we included more patients with preexisting diabetes at baseline compared with previous studies. We used an HbA1c cutoff of ,9.0% as an inclusion criterion, whereas previous studies used a cutoff of ,8.0%. The reduction of the PEGV dose during the first 12 weeks worsened glucose metabolism due to an increase in GH actions. The degree of hyperglycemia after PAS-LAR treatment is dependent on the degree of glycemic control at baseline. The patients who required insulin treatment developed rapid hyperglycemia after the first injection of PAS-LAR. The noninsulin group had a slower onset of hyperglycemia and the diabetes they developed was less severe. In general, their diabetes could be managed after the third injection with oral medication.
We observed an increased frequency of steatorrhea after initiating PAS-LAR treatment, which we ascribed to exocrine pancreatic insufficiency. This is a rare AE during treatment with LA-SSA (32) . Because patients in our study had already been exposed for .6 months to LA-SSAs, we did not expect an increase in the incidence of steatorrhea. Although we did not formally assess exocrine insufficiency, the exogenous addition of exocrine pancreatic enzymes improved the symptoms, and after a few months, most patients could stop this replacement therapy.
Several limitations of our study warrant consideration. First, the efficacy of PAS-LAR we observed at 24 weeks (i.e., after 12 weeks of PAS-LAR treatment) could be influenced by a carryover effect of octreotide LAR or lanreotide ATG following their discontinuation at 12 weeks. After withdrawal of LA-SSA, patients may remain in biochemical remission for up to 4 months, and this appeared to be dependent on the IGF-I level at the time of discontinuation (27, 33) . The efficacy of 73% in our study is higher than reported previously (19, 20) . This may be explained by the carryover effect of firstgeneration LA-SSAs in our study and the fact that patients in our study were controlled before study entry. Second, the diagnosis of diabetes mellitus was based on the American Diabetes Association criteria (27) . Although healthy volunteer data have recommended incretin-based therapies for management of PAS-LARinduced hyperglycemia, in the Netherlands, these drugs are only reimbursed if patients fail on maximum doses of metformin, sulfonylureas, and have a BMI of $35 kg/m 2 (23) . The patients who developed severe hyperglycemia after the first injection had preexisting diabetes, and they all required swift interventions with insulin treatment. Therefore, intensive blood glucose monitoring is required after the start of treatment, and antidiabetic treatment should be promptly initiated, preferably DPP-4 inhibitors and glucagon-like peptide 1 analogues, because treatment with metformin and sulfonylureas appears to be not very effective. Baseline HbA1c levels are the most important predictors for development of diabetes during the study.
GH levels significantly decreased during the study. This is partly caused by the discontinuation and reduction in dose of PEGV but mainly by treatment with PAS-LAR.
Our data indicate that PEGV treatment can neither compensate nor offset PAS-LAR-induced hyperglycemia, probably because PEGV improves insulin sensitivity and the hyperglycemic effect of PAS-LAR is independent of insulin sensitivity and is considered to be more an insulin and incretin suppressive effect (12) (13) (14) (15) 23) . In addition, reducing the PEGV dose that causes active acromegaly may lead to more insulin resistance, whereas treatment with PAS-LAR leads to a further deterioration of glycemic control, especially in patients with (pre)diabetes.
Although the efficacy of PAS-LAR, with or without PEGV, is high, caution should be paid to the long-term sequelae of the pasireotide-induced diabetes. The PEGVsparing effect of PAS-LAR and thereby proposed cost reductions will very likely be consumed by the diabetes mellitus-related medication and health care costs. It is unknown whether patients who initially do not develop pasireotide-induced hyperglycemia have a higher lifetime risk of developing diabetes and could create additional costs. Therefore, more long-term follow-up studies are needed.
In conclusion, PAS-LAR is a viable treatment option in patients previously controlled with combination treatment of first-generation LA-SSA and PEGV. Switching to PAS-LAR enables a reduction in the necessary PEGV dose and/or in a lower number of injections. However, switching to PAS-LAR coincides with a higher frequency of diabetes.
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